ArticlePloS one2009
Development of functional human NK cells in an immunodeficient mouse model with the ability to provide protection against tumor challenge.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity.Frontiers in immunology · 2021Review
- The development of human immune system mice and their use to study tolerance and autoimmunity.Journal of translational autoimmunity · 2019Review
- Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.Cancer immunology, immunotherapy : CII · 2016Review
- Article
- Human hemato-lymphoid system mice: current use and future potential for medicine.Annual review of immunology · 2013Review
- Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.British journal of cancer · 2012Article
- Article
- Mice with human immune system components as in vivo models for infections with human pathogens.Immunology and cell biology · 2011Review
- Humanized mice are susceptible to Salmonella typhi infection.Cellular & molecular immunology · 2011Article
- Article
- Humanized mouse models of HIV infection.AIDS reviewsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Studies of human NK cells and their role in tumor suppression have largely been restricted to in vitro experiments which lack the complexity of whole organisms, or mouse models which differ significantly from humans. In this study we showed that, in contrast to C57BL/6 Rag2(-/-)/gamma(c) (-/-) and NOD/Scid mice, newborn BALB/c Rag2(-/-)/gamma(c) (-/-) mice can support the development of human NK cells and CD56+ T cells after intrahepatic injection with hematopoietic stem cells. The human CD56(+) cells in BALB/c Rag2(-/-)/gamma(c) (-/-) mice were able to produce IFN-gamma in response to human IL-15 and polyI:C. NK cells from reconstituted Rag2(-/-)/gamma(c) (-/-) mice were also able to kill and inhibit the growth of K562 cells in vitro and were able to produce IFN-gamma in response to stimulation with K562 cells. In vivo, reconstituted Rag2(-/-)/gamma(c) (-/-) mice had higher survival rates after K562 challenge compared to non-reconstituted Rag2(-/-)/gamma(c) (-/-) mice and were able to control tumor burden in various organs. Reconstituted Rag2(-/-)/gamma(c) (-/-) mice represent a model in which functional human NK and CD56+ T cells can develop from stem cells and can thus be used to study human disease in a more clinically relevant environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.